Nivolumab maintains function, reduces symptoms in treatment of relapsed metastatic head and neck cancer

Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial.
Source: Feed4

Leave a Reply

Your email address will not be published. Required fields are marked *